Bon Natural Life Limited (BON) AI Stock Analysis

Bon Natural Life Limited, established in 2006 and headquartered in Grand Cayman, Cayman Islands, specializes in the research, development, manufacturing, and global distribution of functional active ingredients derived from natural herbs. The company serves clients in the People's Republic of China and internationally. Its portfolio includes personal care ingredients, such as plant-extracted fragrance compounds for perfume and fragrance makers, alongside natural health supplements including powder drinks and bioactive food additives. These products are supplied across functional foods, personal care, cosmetics, and pharmaceutical sectors.

Revenue increased from $25.5M in FY2021 to $29.9M in FY2022 before falling to $29.5M in FY2023, $23.8M in FY2024, and $18.7M in FY2025, representing a 5-year revenue CAGR of 0.5%. Gross margin narrowed from 27.9% in FY2021 and 31.5% in FY2022 to 20.8% in FY2025. Operating margin shifted from positive 21.2% in FY2021 to -8.7% in FY2025, while net income shifted from $4.6M to -$2.0M over the same period. For the trailing twelve months ending June 30, 2026, revenue stood at $18.8M with a profit margin of -60.4% and an operating margin of -82.2%. In the latest quarter, quarterly revenue grew 1.9% year-over-year, while quarterly earnings fell 41.0%.

As of June 30, 2026, Bon Natural Life held $9.2M in cash and short-term investments against total debt of $12.3M, resulting in net debt of $3.1M. Shareholders' equity was $50.8M against total assets of $80.2M. The company maintained a current ratio of 1.83 and a debt-to-equity ratio of 0.24. In FY2025, operating cash flow was $141,115 and capital expenditures were $4.4M, resulting in free cash flow of -$4.2M. Over the trailing five years, the company's share count increased 700.1%.

At a closing price of $1.14 on October 16, 2026, Bon Natural Life had a market cap of $9.3M and an enterprise value of $18.3M. The stock traded at a forward P/E of 2.3x, below the 13.4x median of its US-listed Basic Materials peers. Its EV to EBITDA multiple was 2.9x compared to the peer median of 10.5x, and its price-to-sales was 0.5x versus the peer median of 1.8x. Over the past year, the stock fell 46.9%, while the S&P 500 gained 16.8%. Over five years, the stock fell 99.9% compared to an 83.0% gain for the benchmark.

Analysts tracked for Bon Natural Life have set a mean price target of $77.50, representing an upside comparison of 6722.2% relative to the last close of $1.14 on October 16, 2026. In terms of earnings performance against consensus, the company achieved 3 EPS beats over the last 4 quarters. No additional analyst ratings, consensus recommendation counts, or upcoming earnings dates are provided in the available reporting.

This page is an AI-written research summary of Bon Natural Life Limited (BON). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BON income statement, BON balance sheet, BON key metrics, BON chart. See the BON stock overview for the latest quote and news.